Drug Trial Radar · NCT01352663
Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients
Last checked: Nov 20, 2026Latest source record: Oct 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- WockhardtIndustry
- Sponsor type
- Industry
- First posted
- May 12, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, randomized, parallel group comparison of the immunogenicity safety of Wockhardt's Recombinant Insulin Analogue with the innovator's Glargine in Type 1 diabetics patients.
Conditions
- Type I Diabetes
Interventions
Wockhardt's Insulin Analogue (Recomb)Biological
Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
Lantus®Biological
Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbAlc from baseline till the end of treatment period.Time frame: 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.